Literature DB >> 6662838

Staphylococcal central nervous system infections treated with cloxacillin.

I W Fong.   

Abstract

A retrospective review of 20 patients with staphylococcal central nervous system (CNS) infections treated with cloxacillin is presented. Eleven of these patients had Staphylococcus aureus meningitis secondary to neurosurgery or spontaneously induced. Six patients had ventricular shunt or drainage infection, two secondary to Staph. aureus and five grew Staph. epidermidis (with one mixed infection). Three patients presented with brain abscess, one with mixed anaerobic infection and all grew Staph. aureus. Cure with cloxacillin was achieved in 15 of the 20 patients. Failure of therapy was associated with doses of 6 g or less per day, and cure with doses of 12 g or more per day. Cloxacillin is effective in staphylococcal CNS infections when used in large parenteral doses.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6662838     DOI: 10.1093/jac/12.6.607

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

Review 1.  Staphylococcal adaptation to diverse physiologic niches: an overview of transcriptomic and phenotypic changes in different biological environments.

Authors:  Sana S Dastgheyb; Michael Otto
Journal:  Future Microbiol       Date:  2015-11-19       Impact factor: 3.165

2.  The passage of cloxacillin into cerebrospinal fluid in the absence of meningitis.

Authors:  H I Schievink; H Mattie; R T Thomeer; E Van Strijen
Journal:  Br J Clin Pharmacol       Date:  1993-07       Impact factor: 4.335

3.  A rare case of acute transverse myelitis associated with Staphylococcusaureus bacteremia and osteomyelitis.

Authors:  Stamatis Karakonstantis; Despoina Galani; Sevasti Maragou; Asimina Koulouridi; Dimitra Kalemaki; Charalampos Lydakis
Journal:  Spinal Cord Ser Cases       Date:  2017-05-25

Review 4.  Penicillins. A current review of their clinical pharmacology and therapeutic use.

Authors:  Dilip Nathwani; Martin J Wood
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.